EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG successfully completes capital increase

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.

Ad-hoc release

SYGNIS Pharma AG successfully completes capital increase

Heidelberg, 10 August 2011 - The shareholders of SYGNIS  Pharma  AG  (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) exercised their subscription and  over-
subscription  rights  for  3,076,623  new  no-par  value  bearer  shares  at   a
subscription price of euro 2.00 per new share by the  end  of  the  subscription
period on 9 August 2011.

SYGNIS plans to use the gross proceeds of approximately euro 6.15  million  from
this capital increase to finance in particular the completion and the  potential
commercialization of its current efficacy trial of AX200 for  the  treatment  of
acute stroke (AXIS 2) as well as  the  development  of  its  preclinical  KIBRA-

SYGNIS' main  shareholder  -  dievini  Hopp  BioTech  holding  GmbH  &  Co.  KG,
Walldorf, Germany - has exercised its subscription and over-subscription  rights
for a total of 3 million new shares at the subscription  price.  In  receipt  of
these new shares dievini has invested funds equal  to  the  loan-amount  dievini
has committed in June 2011. According to  the  contractual  terms  of  the  loan
agreement such  commitment  ceases  to  apply  automatically  with  this  equity
investment. As a  result,  dievini  will  hold  approximately  54,5%  of  shares
outstanding in SYGNIS.

Following the entry of the capital increase in the Commercial Register  -  which
is scheduled for 15 August 2011 - the total number of SYGNIS shares issued  will
increase to 16,829,504. Accordingly the equity capital will increase  from  euro
13,752,881 to euro 16,829,504. The subscribed and allocated  new  SYGNIS  shares
are expected to  be  delivered,  after  they  have  been  listed  on  the  stock
exchange, and to begin trading on the stock exchange  on  17  August  2011.  The
capital increase is being conducted by Landesbank Baden-Württemberg,  Stuttgart,

For further information please contact:

|Dr. Franz-Werner Haas                   |
|Senior VP  Operations                   |
|Tel: +49 (0) 6221-454 812               |
|Email:   |

### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. The shares in SYGNIS Pharma
AG (the 'Shares') may not be offered or sold in the United States or to or for
the account or benefit of 'U.S. persons' (as such term is defined in Regulation
S under the U.S. Securities Act of 1933, as amended (the 'Securities Act')). No
offer or sale of transferable securities is being made to the public. The

shares are offered solely on the basis of subscription rights.

This document is only being distributed to and is only directed at (i) persons
who are outside the United Kingdom or (ii) to investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the 'Order') or (iii) high net worth entities, and other
persons to whom it may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being referred to as
'relevant persons'). The Shares are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, relevant persons. Any person who is not a
relevant person should not act or rely on this document or any of its contents.

Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason.

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: